Christine Gruessner1, Angelika Gruessner2, Katherine Glaser3, Nisreen Abushahin4, Cynthia Laughren5, Wenxin Zheng6, Setsuko K Chambers7. 1. College of Medicine, University of Arizona Tucson, AZ, USA. 2. Mel and Enid Zuckerman College of Public Health, University of Arizona Tucson, AZ, USA. 3. College of Medicine, University of Arizona Tucson, AZ, USA ; Department of Obstetrics and Gynecology, University of Arizona Tucson, AZ, USA. 4. Department of Pathology, University of Jordan Amman, Jordan ; Department of Pathology, University of Arizona Tucson, AZ, USA. 5. University of Arizona Cancer Center Tucson, AZ, USA. 6. College of Medicine, University of Arizona Tucson, AZ, USA ; University of Arizona Cancer Center Tucson, AZ, USA ; Department of Pathology, University of Arizona Tucson, AZ, USA. 7. College of Medicine, University of Arizona Tucson, AZ, USA ; Department of Obstetrics and Gynecology, University of Arizona Tucson, AZ, USA ; University of Arizona Cancer Center Tucson, AZ, USA.
Abstract
INTRODUCTION: BRCA mutations increase the risk for development of high-grade pelvic serous carcinomas. Tissue biomarkers distinguishing women at high-risk (HR) for ovarian cancer from those at low-risk (LR) may provide insights into tumor initiation pathways. METHODS: A prospective study of 47 HR women (40% BRCA carriers) undergoing risk-reducing salpingo-oophorectomy and 48 LR controls undergoing salpingo-oophorectomy was performed. Ovarian/tubal tissues were harvested. Immunohistochemical analysis of candidate proteins CSF-1, CSF-1R, ErbB4 is presented, with scores separately analyzed in epithelium and stroma, in ampulla, fimbria, ovary, and ovarian endosalpingiosis (ES). Comparison was performed between HR and LR groups. RESULTS: Elevated levels of CSF-1 (p=0.005) or ErbB4 (p=0.005) in the ovarian epithelium, or ErbB4 (p=0.005) in the ovarian stroma, were significantly associated with both the HR status and carrying a BRCA mutation, as was nuclear ErbB4 staining. Ovarian ES, an entity which likely derives from the tubal mucosal epithelium, was also associated with HR (p=0.038) and BRCA mutation status (p=0.011). Among the BRCA carriers only, markers also found association when present in the tube as well as in ovarian ES (p < 0.05). ROCs were generated including in the regression model both CSF-1 and ErbB4 expression levels. A model including CSF-1 in ovarian epithelium, ErbB4 in ovarian stroma, and younger age achieves AUC=0.87 (73% sensitivity, 93% specificity) of detection of the HR status. In BRCA carriers, CSF-1 in ovarian epithelium alone achieves AUC=0.85. CONCLUSIONS: Our data suggest that elevated levels of CSF-1/ErbB4 in the adnexae correlate with HR/BRCA carrier status. CSF-1/CSF-1R signaling is active in ovarian cancer progression; our data suggests a role in its initiation. ErbB4, in particular nuclear ErbB4, may have a role in tumor initiation as well. Ovarian ES, an entity which may represent a latent precursor to low-grade pelvic serous carcinomas, was surprisingly associated with both HR status and the BRCA carrier cohort. In line with these findings, both ErbB4 and CSF-1R expression in ovarian ES correlated with carrying a BRCA mutation. This analysis, which needs to be validated, indirectly suggests a potential link between ovarian ES and the development of pelvic serous carcinoma in women who are BRCA mutation carriers.
INTRODUCTION:BRCA mutations increase the risk for development of high-grade pelvic serous carcinomas. Tissue biomarkers distinguishing women at high-risk (HR) for ovarian cancer from those at low-risk (LR) may provide insights into tumor initiation pathways. METHODS: A prospective study of 47 HR women (40% BRCA carriers) undergoing risk-reducing salpingo-oophorectomy and 48 LR controls undergoing salpingo-oophorectomy was performed. Ovarian/tubal tissues were harvested. Immunohistochemical analysis of candidate proteins CSF-1, CSF-1R, ErbB4 is presented, with scores separately analyzed in epithelium and stroma, in ampulla, fimbria, ovary, and ovarian endosalpingiosis (ES). Comparison was performed between HR and LR groups. RESULTS: Elevated levels of CSF-1 (p=0.005) or ErbB4 (p=0.005) in the ovarian epithelium, or ErbB4 (p=0.005) in the ovarian stroma, were significantly associated with both the HR status and carrying a BRCA mutation, as was nuclear ErbB4 staining. Ovarian ES, an entity which likely derives from the tubal mucosal epithelium, was also associated with HR (p=0.038) and BRCA mutation status (p=0.011). Among the BRCA carriers only, markers also found association when present in the tube as well as in ovarian ES (p < 0.05). ROCs were generated including in the regression model both CSF-1 and ErbB4 expression levels. A model including CSF-1 in ovarian epithelium, ErbB4 in ovarian stroma, and younger age achieves AUC=0.87 (73% sensitivity, 93% specificity) of detection of the HR status. In BRCA carriers, CSF-1 in ovarian epithelium alone achieves AUC=0.85. CONCLUSIONS: Our data suggest that elevated levels of CSF-1/ErbB4 in the adnexae correlate with HR/BRCA carrier status. CSF-1/CSF-1R signaling is active in ovarian cancer progression; our data suggests a role in its initiation. ErbB4, in particular nuclear ErbB4, may have a role in tumor initiation as well. Ovarian ES, an entity which may represent a latent precursor to low-grade pelvic serous carcinomas, was surprisingly associated with both HR status and the BRCA carrier cohort. In line with these findings, both ErbB4 and CSF-1R expression in ovarian ES correlated with carrying a BRCA mutation. This analysis, which needs to be validated, indirectly suggests a potential link between ovarian ES and the development of pelvic serous carcinoma in women who are BRCA mutation carriers.
Authors: C van Haaften-Day; Y Shen; F Xu; Y Yu; A Berchuck; L J Havrilesky; H W de Bruijn; A G van der Zee; R C Bast; N F Hacker Journal: Cancer Date: 2001-12-01 Impact factor: 6.860
Authors: Ilkka Paatero; Heini Lassus; Teemu T Junttila; Matti Kaskinen; Ralf Bützow; Klaus Elenius Journal: Gynecol Oncol Date: 2013-01-09 Impact factor: 5.482
Authors: Anna C Nelson-Moseke; Joanne M Jeter; Haiyan Cui; Denise J Roe; Setsuko K Chambers; Christina M Laukaitis Journal: Fam Cancer Date: 2013-03 Impact factor: 2.375
Authors: Sian M Tovey; Caroline J Witton; John M S Bartlett; Peter D Stanton; Jonathan R Reeves; Timothy G Cooke Journal: Breast Cancer Res Date: 2004-03-23 Impact factor: 6.466
Authors: Pui-Wah Choi; Wai Wing So; Junzheng Yang; Shubai Liu; Ka Kui Tong; Kin Ming Kwan; Jamie S-L Kwok; Stephen K W Tsui; Shu-Kay Ng; Karen H Hales; Dale B Hales; William R Welch; Christopher P Crum; Wing-Ping Fong; Ross S Berkowitz; Shu-Wing Ng Journal: Oncogene Date: 2020-03-25 Impact factor: 9.867